Form 4: BioCryst Legal Officer Sells Shares Under 10b5-1 Plan

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, executed a pre-planned sale of 150,000 common shares following the exercise of stock options.

Summary

• Alane P. Barnes, Chief Legal Officer of BIOCRYST PHARMACEUTICALS INC (BCRX), engaged in a transaction on March 16, 2026.
• The transaction involved the acquisition of 150,000 shares of common stock through the exercise of employee stock options at a price of $5.51 per share.
• Concurrently, 150,000 shares of common stock were disposed of at a weighted average price of $9.15 per share, with individual sales ranging from $8.95 to $9.57.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Ms. Barnes on August 13, 2025, indicating a pre-scheduled, non-discretionary event.
• Following these transactions, Ms. Barnes beneficially owns 400,703 shares of common stock directly.
• The employee stock option, with an exercise price of $5.51, became exercisable at a rate of 25% on each of the first, second, third, and fourth anniversaries of the grant date, February 27, 2018, and expires on February 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, the execution under a pre-established 10b5-1 plan reduces the negative signaling typically associated with insider selling, as it's not a discretionary decision based on recent information.

Positives

• The exercise of employee stock options indicates that the company's stock price was above the option's exercise price of $5.51, allowing the Chief Legal Officer to realize a gain.
• The transaction was executed under a Rule 10b5-1 plan, which demonstrates pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• The sale of 150,000 shares by a key executive, even if pre-planned, represents a reduction in insider ownership, which can sometimes be perceived negatively by the market.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences. While a sale by an executive reduces their direct stake, the pre-planned nature often mitigates concerns about immediate negative sentiment regarding the company's prospects, as these plans are set up in advance to allow insiders to diversify holdings without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan suggests it's for personal financial planning rather than a reflection of the company's immediate prospects. The sale could exert minor downward pressure on the stock price if perceived negatively.

Key Dates

Recommendation

The transaction is an insider sale, but its execution under a pre-arranged 10b5-1 plan suggests it's for personal financial management rather than a direct reflection of the executive's current outlook on the company's immediate future. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, leading to a 'hold' stance for seasoned investors.

Keywords

BioCryst Pharmaceuticals, BCRX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Legal Officer, Alane P. Barnes